ThymoQuin®-OCare Black Seed Oil Now Applicable for Oral Health

Thymo-Quin®-OCare is a cold-pressed, full-spectrum black seed oil standardized to 3% thymoquinone with at least 1.2% p-Cymene and less than 1.25% free fatty acids. It's oral health applications include mouth wash, toothpaste and dietary supplements.

TriNutra and its Korean partner, HuTri Corporation, have announced the use of ThymoQuin®OCare, a cold-pressed, full-spectrum black seed oil standardized to 3% thymoquinone with at least 1.2% p-Cymene (the main bio-actives in black seed with synergistic action) and less than 1.25% free fatty acids, is now a potent ingredient for improved halitosis (bad breath) and sensitive teeth.

“We are thrilled to supply the first patent pending ThymoQuin oral health care product. ThymoQuinOCare is a powerful, plant-based option for improved oral health. We have been working on this project for a while, analyzing several BSO sources, and testing them in vitro compared to existing popular products. We found that the full spectrum BSO, standardized thymoquinone level, higher ratio of thymoquinone to p-cymene (at least 3:1 ) and low free fatty acids – by far, improve oral health” said Alex Chuyoun Song, CEO at HuTri Corporation.

Black seed oil’s main active constituent is thymoquinone and is unstable in the presence of oxidants, like free fatty acids – which naturally occur in the plant. This leads to reduced potency of the black seed oil and rancidity. It was, therefore, a major goal of TriNutra to find a way to standardize and stabilize its black seed oil. TriNutra’s ThymoQuin is the first cold-pressed, full-spectrum black seed oil standardized to 3% thymoquinone and p-cymene (min. 1.2%) with very low levels of free fatty acids (FFA) (less than 1.25%). This patented composition offers potent health benefits with increased bioavailability.

ThymoQuin®-OCare is the only black seed oil that is full­spectrum and standardized to the two main actives from black seed and with low FFA.

“HuTri Corporation has been a great partner in spearheading the research behind ThymoQuin’s oral health capacity which is now specially branded as ThymoQuin®-OCare,” said Morris Zelkah, CEO at TriNutra. “We are excited about the opportunity ThymoQuin®-OCare presents in this category as it con tinues to demonstrate superior results.” www.trinutra.com service@trinutra.com

This announcement follows ThymoQuin’s meeting of the USP monograph standards, its European patent for improved stability and bioavailability, and its US patent for the composition and synergistic effects of ThymoQuin with Omega-3.

ThymoQuin®-OCare’s oral health applications include, but are not limited to, mouth wash, toothpaste and dietary supplements.